{"id":"atl-104","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL3663410","moleculeType":"Small molecule","molecularWeight":"408.44"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Glucagon receptor antagonists are a class of drugs that block the action of glucagon, a hormone that raises blood glucose levels. By blocking glucagon, ATL-104 is expected to lower blood glucose levels and improve glycemic control in patients with diabetes.","oneSentence":"ATL-104 is a glucagon receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:28.692Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00163280","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis","status":"COMPLETED","sponsor":"Alizyme","startDate":"2004-07","conditions":"Mucositis","enrollment":63}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ATL-104","genericName":"ATL-104","companyName":"Alizyme","companyId":"alizyme","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATL-104 is a glucagon receptor antagonist. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}